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Labeled
• cryopyrin-associated periodic
syndromes (CAPS)
• rheumatoid arthritis
Off-Label
• coronavirus disease 2019 (COVID-19) † • severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection 
†
† Off-label indication
INVESTIGATIONAL USE: For adjunctive use in the treatment of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection†, the 
virus that causes coronavirus disease 2019 (COVID-19)†
Intravenous dosage
• Adults
Efficacy has not been established. Due to a lack of clinical data, the National Institutes of
Health (NIH) COVID-19 treatment guidelines do not give recommendations for or against
the use of IL-1 receptor inhibitors, such as anakinra.[65314] 100 mg via intravenous
infusion given every 6 hours for 15 days is being evaluated. In SARS-CoV-2 infected
patients with macrophage activation syndrome (MAS) or immune dysregulation, one study
is evaluating 200 mg intravenously every 8 hours for 7 days. For patients with renal
impairment, the dose is to be reduced to 100 mg intravenously every 8 hours for 15 days.
[65233] [65234]
Subcutaneous dosage
• Adults
Efficacy has not been established. Due to a lack of clinical data, the National Institutes of 
Health (NIH) COVID-19 treatment guidelines do not give recommendations for or against 
the use of IL-1 receptor inhibitors, such as anakinra.[65314] 100 mg once daily via 
subcutaneous injection for 28 days or until hospital discharge, whichever is first, is being 
evaluated.[65194]
For the treatment of moderately to severely active rheumatoid arthritis in 
patients who have failed 1 or more disease-modifying antirheumatic drugs 
(DMARDs)
Subcutaneous dosage
• Adults
100 mg subcutaneously once daily, every 24 hours, at approximately the same time each
day. Higher doses do not result in increased response. Anakinra may be given alone or in
combination with DMARDs other than tumor necrosis factor (TNF) inhibitors.[27940]
For the treatment of cryopyrin-associated periodic syndromes (CAPS), 
specifically Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
Subcutaneous dosage
• Adults
1 to 2 mg/kg subcutaneously once daily, initially. If needed, increase by 0.5 to 1 mg/kg
increments. In a clinical trial, the average maintenance dose was 3 to 4 mg/kg/day. Usually
given as a single daily dose. However, splitting the daily dose into twice daily
administrations may result in better symptom control for some patients. Max: 8 mg/kg/day.
[27940]
• Infants, Children, and Adolescents
1 to 2 mg/kg subcutaneously once daily, initially. If needed, increase by 0.5 to 1 mg/kg
increments. In a clinical trial, the average maintenance dose was 3 to 4 mg/kg/day. Usually
given as a single daily dose. However, splitting the daily dose into twice daily
administrations may result in better symptom control for some patients. Max: 8 mg/kg/day.
The NOMID premarket clinical trial included 36 pediatric patients, 13 of which were
younger than 2 years; the youngest patient studied was 8 months of age.[27940] In a
retrospective study of 10 patients (2 months to 20 years of age), the 8 oldest patients
(ages 6 to 20 years) required dosages of 1 to 3 mg/kg/day, whereas the 2 youngest 
patients (3 and 4 months) had severe disease and required 6 and 10 mg/kg/day to control 
symptoms.[56308]
Therapeutic Drug Monitoring
Check the patient's neutrophil count before anakinra initiation, followed by monthly for the first 3 
months of therapy, and then quarterly for up to 1 year.[27940]
Maximum Dosage Limits
• Adults 
100 mg/day subcutaneously for RA; 8 mg/kg/day subcutenously for NOMID.
• Geriatric 
100 mg/day subcutaneously for RA.
• Adolescents 
8 mg/kg/day subcutaneously for NOMID.
• Children 
8 mg/kg/day subcutaneously for NOMID.
• Infants 
8 mg/kg/day subcutaneously. Limited data available in young infants; up to 10 
mg/kg/day subcutaneously has been used off-label in an infant with severe NOMID.
• Neonates 
Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing
Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that 
no dosage adjustments are needed.
Patients with Renal Impairment Dosing
CrCl 30 mL/minute or more: No dosage adjustment needed.
CrCl less than 30 mL/minute: Increased risk of adverse reactions; consider administration of the 
prescribed dose every other day instead of daily for both RA and NOMID.
† Off-label indication
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How Supplied
Anakinra Solution for injection
Kineret 100mg/0.67ml Solution for Injection (55513-0177) 
(Amgen Inc) (off market)
Anakinra Solution for injection
Kineret 100mg/0.67ml Solution for Injection (55513-0177) 
(SOBI ab) (off market)
Kineret 100mg/0.67ml Solution for Injection (66658-0234) (SOBI ab) 
Description/Classification
Description
Anakinra is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist 
(IL-1Ra). The drug is produced by recombinant DNA technology using an E. coli bacterial 
expression system. Anakinra is useful for treating rheumatoid arthritis (RA) and some other 
inflammatory conditions. In adults with moderately to severely active RA, anakinra improves 
signs and symptoms of the disease and slows the progression of structural damage. Anakinra was 
considered but not included in the American College of Rheumatology 2015 guidelines due to its 
infrequent use at that time in RA compared to other available treatments and lack of new data 
since 2012; however, tumor necrosis factor (TNF) inhibitors are usually first-line choices in the 
biologic treatment categories due to the long-term safety data and the amount of experience 
associated with the TNF biologics.[65215] For adult RA, anakinra may be used as monotherapy; 
the drug may also be used with other disease-modifying antirheumatic drugs (DMARDs). The 
ideal combination of therapy for individual RA patients is determined by treat to target strategies 
and severity of disease.[56233] [65215] While anakinra has been studied in pediatric patients 2 
years and older with polyarticular juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis 
(JIA), the study data were insufficient to establish efficacy for this condition, and use for JRA/JIA 
is not recommended. Anakinra is helpful for the treatment of Cryopyrin-Associated Periodic 
Syndromes (CAPS) such as Muckle-Wells Syndrome (MWS), Familial Cold Auto-Inflammatory 
Syndrome (FCAS), and Neonatal-Onset Multisystem Inflammatory Disease (NOMID), which is 
also called Chronic Infantile Neurological, Cutaneous and Articular Syndrome (CINCA). Of all 
the forms of CAPS, NOMID/CINCA has the highest severity of chronic inflammation. Among 
patients with NOMID, disease symptoms and serum markers of inflammation usually worsened 
within 5 days of anakinra withdrawal and promptly responded to anakinra re-initiation.[27940]
[33464] [33465] [33468] [33469]
Updates for coronavirus disease 2019 (COVID-19):
Due to a lack of clinical data, the National Institutes of Health (NIH) COVID-19 treatment 
guidelines do not give recommendations for or against the use of IL-1 receptor inhibitors, such as 
anakinra.[65314] Based on preliminary data from other anti-interleukin medications, studies have 
begun to evaluate the use of anakinra for COVID-19.[65194] [65233] [65234]
Classifications
• Antineoplastic and Immunomodulating Agents
◦ Agents that Suppress the Immune System
◾ Interleukin-1 (IL-1) Inhibitors
• Musculo-Skeletal System
◦ Antiinflammatory Agents and Antirheumatic Agents
◾ Specific Anti-Rheumatic Agents
◾ Other Specific Antirheumatics
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Administration Information
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Injectable Administration
• Prefilled syringes are for subcutaneous administration.
• Visually inspect parenteral products for particulate matter and discoloration prior to 
administration whenever solution and container permit.
• Do not use the prefilled syringe if the solution is discolored or cloudy or if foreign 
particulate matter is present. Trace amounts of small, translucent-to-white, amorphous 
particles of protein may be in the solution. However, do not use the syringe if the 
number of translucent-to-white, amorphous particles appears excessive.[27940]
Subcutaneous Administration
• Instructions for appropriate use should be given to the patient and/or patient's 
caregiver. Patients or patient's caregiver should not administer anakinra until they have 
demonstrated a thorough understanding of the procedures and the ability to inject the 
medication.
• Inject the subcutaneous dose at about the same time(s) each day.[27940]
Prefilled Syringe:
• Remove the prefilled syringe from the refrigerator and allow it to sit at room 
temperature outside of the carton for 30 minutes before the injection. Do not warm 
anakinra in any other way.
• Wash hands before administration.
• The prefilled syringe does not allow doses lower than 20 mg to be administered. For a 
dose that is less than 100 mg, follow the manufacturer directions for preparing the dose 
needed. Small air bubbles may be present in the solution and do not need to be 
removed prior to administration.
• Pick an injection site such as the front of the middle thigh, the abdomen outside the 2 
inches around the navel, the upper outer buttocks, or the outer area of the upper arm. 
Do not administer where skin is tender, bruised, red, or hard. Do not administer into 
scars or stretch marks. Do not inject near a vein that is visible under the skin surface.
• Rotate injection sites with each injection.
• Clean the injection site with the alcohol swab and let dry.
• Gently pinch a fold of skin at the cleaned injection site. With your other hand, hold the 
syringe like a pencil at a 45 to 90-degree angle to the skin. With a quick, dart-like 
motion insert the needle into the skin.
• Slowly push the plunger down to inject the dose. When the syringe is empty, remove 
the needle from the skin at the same angle it was inserted. Do not recap the needle.
• Dispose of used needles and syringes in an FDA-cleared sharps disposal container right 
away after use. The prefilled syringes do not contain preservatives and are for single-
use only. If a syringe contains medicine after administration, it should be disposed of 
properly and not reused.[27940]
Clinical Pharmaceutics Information
From Trissel's 2™ Clinical Pharmaceutics Database 
Anakinra
1. pH Range
pH 6.5
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2. Osmolality/Osmolarity
Based on the formulation, anakinra injection should be near isotonicity.
References
Anon. Manufacturer's information and labeling. (Package insert). 
3. Stability
Intact syringes of anakinra are stable until their labeled expiration date but should not 
be used past that time point. Anakinra syringes are for single use and contain no 
preservative. Any unused portions remaining in the syringes should be discarded. Do 
not shake syringes.
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4. Sorption Leaching
Polysorbate 80, a surfactant known to leach diethylhexyl phthalate plasticizer from 
polyvinyl chloride (PVC) infusion solution bags and sets, is a component of the 
formulation of anakinra. However, the surfactant is present in small quantity and 
substantial leaching of plasticizer is not likely to occur.
References
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Adverse Reactions
• abdominal pain
• anaphylactoid reactions
• angioedema
• antibody formation
• arthralgia
• diarrhea
• ecchymosis
• elevated hepatic enzymes
• eosinophilia
• fever
• headache
• hepatitis
• hypercholesterolemia
• infection
• injection site reaction
• nausea
• neutropenia
• new primary malignancy
• pharyngitis
• pruritus
• rash
• sinusitis
• thrombocytopenia
• urticaria
• vomiting
Hypersensitivity reactions including anaphylactoid reactions, angioedema, urticaria, rash
(unspecified), and pruritus have been reported with the use of anakinra. If a severe 
hypersensitivity reaction occurs, discontinue anakinra and initiate appropriate therapy.[27940]
The most common adverse reaction of anakinra subcutaneous administration is injection site 
reaction, which usually occurs during the first 4 weeks of treatment and is more common in 
patients with rheumatoid arthritis (RA) than in patients with Neonate-Onset Multisystem 
Inflammatory Disease (NOMID). In clinical trials of patients with RA (n= 1,565), 71% of patients 
developed an injection site reaction; 72.6% were characterized as mild, 24.1% as moderate, and 
3.2% as severe. In an open-label trial of NOMID patients (n = 43), 16.3% experienced an injection 
site reaction; during the 60-month study period, 65% of the injection site reactions occurred 
during the first month and 76% were reported during the first 6 months; 76% were characterized 
as mild and 24% as moderate. These reactions typically last for 14 to 28 days and are 
characterized by localized erythema, ecchymosis, edema, inflammation, itching, and/or pain. To 
decrease pain, swelling, and bruising at the injection site, apply a cold compress before and/or 
after the injection and allow the solution warm to room temperature prior to injection.[27940]
Anakinra has been associated with an increased risk of serious infections during clinical trials. 
Anakinra may increase the risk of tuberculosis (TB) or other atypical opportunistic infections. 
During postmarketing observation and in clinical studies, opportunistic infections consisting of 
fungal, mycobacterial, and bacterial pathogens have occurred. Infections have been noted in all 
organ systems and have been reported in patients receiving anakinra alone or in combination with 
immunosuppressive agents. Anakinra should be discontinued in patients with rheumatoid arthritis 
(RA) who develop a serious infection. In anakinra-treated patients with Neonatal-Onset 
Multisystem Inflammatory Disease (NOMID), the risk of a NOMID flare when discontinuing 
anakinra should be weighed against the potential risk of continued treatment. During RA clinical 
trials, the incidence of infection during the first 6 months in anakinra-treated patients was 39% vs. 
37% in placebo-treated patients. Reported infections in RA patients included upper respiratory 
tract infections (14%), sinusitis (7%), and influenza-like symptoms (6%). Serious infections 
occurred in 2% of anakinra-treated RA patients over 6 months of therapy and 3% of treated 
patients after over 1 year of therapy. The serious infections were primarily bacterial infections 
such as cellulitis, pneumonia, and bone and joint infections. In open-label extension studies, the 
overall rate of serious infections was comparable to that observed during controlled trials. The use 
of TNF blockers with anakinra should be avoided. In RA patients who received both anakinra and 
a TNF blocker (etanercept) for up to 24 weeks, the incidence of serious infections was 7%. The 
most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One 
patient with pulmonary fibrosis and pneumonia died due to respiratory failure. RA patients with 
asthma had a higher incidence of serious infections during treatment with anakinra versus 
placebo-treated patients (4.5% vs 0%). In an open-label study of 43 patients with NOMID, 
infections were the most common type of serious adverse event; reporting frequency was highest 
in pediatric patients less than 12 years of age and those younger than 2 years had the highest 
incidence of infection and related symptoms. The most common infections were upper respiratory 
tract infection, sinusitis, ear infections (otitis media), and naso-pharyngitis (11.6%). The most 
common serious infections in NOMID patients were pneumonia and gastroenteritis. There were no 
deaths or permanent treatment discontinuation due to infection. Most NOMID patients (73%) have 
continued anakinra therapy once the infection resolved.[27940]
Anakinra treatment has been associated with hematologic side effects, including neutropenia. 
Monitoring of the absolute neutrophil count (ANC) is recommended prior to and during the first 
year of treatment with anakinra (monitor at baseline, each month for 3 months, then quarterly). In 
clinical trials, 8% of patients with rheumatoid arthritis (RA) receiving anakinra had decreases in 
neutrophil counts of at least one World Health Organization (WHO) toxicity grade compared with 
2% in the control group. Neutropenia (ANC 1,000/mm3 or less) was reported in 9 anakinra-treated 
patients (0.4%) and in 2% of patients treated with anakinra plus etanercept. Two of 43 (4.7%) 
patients with Neonatal-Onset Multisystem Inflammatory Disease (NOMID) experienced 
neutropenia after starting anakinra in a clinical trial; both cases resolved during continued 
anakinra treatment. In RA trials, a total of 9% of anakinra recipients experienced increases in 
eosinophil differential percentage (eosinophilia) of at least 1 WHO toxicity grade compared to 3% 
of placebo-treated patients. WHO toxicity grade 1 decreases in platelet countss occurred in 2% of 
anakinra treated-patients and 0% of placebo-treated patients. Thrombocytopenia, including severe 
thrombocytopenia (i.e., platelet count less than 10,000/mm3), has been reported with the 
postmarket use of anakinra.[27940]
Adverse gastrointestinal (GI) events reported in 5% or more of patients treated with anakinra 
during rheumatoid arthritis clinical trials include nausea (8%), diarrhea (7%), and abdominal pain
(5%). In an open-label study in 43 NOMID patients, vomiting (14%) was the most common GI 
adverse event.[27940]
Headache and arthralgia are two of the most common adverse reactions to anakinra treatment. 
Headache occurred in 12% to 14% of patients during all clinical trials. Arthralgia occurred in 6% 
of anakinra-treated patients during rheumatoid arthritis (RA) clinical trials over a 6 month period 
and in 11.6% of 43 patients in a study of anakinra for Neonatal-Onset Multisystem Inflammatory 
Disease (NOMID). In the RA trials, a total of 19% of anakinra recipients experienced worsening 
of rheumatoid arthritis, compared to 29% of placebo recipients.[27940]
In an open-label study in 43 patients with Neonatal-Onset Multisystem Inflammatory Disease 
(NOMID), treatment-emergent pyrexia (fever) was reported in 11.6% of patients. Fever was not 
reported as an adverse event in clinical trials of patients with rheumatoid arthritis.[27940]
Cholesterol elevations were observed in some patients treated with anakinra therapy 
(hypercholesterolemia incidence not reported).[27940]
Elevated hepatic enzymes and non-infectious hepatitis have been reported postmarketing with the 
use of anakinra.[27940]
As with all therapeutic proteins, the use of anakinra carries the risk for immunogenicity. Antibody 
formation to anakinra detected by the use of a highly sensitive anakinra-binding biosensor assay 
was present at least once over 36 months in 49% of patients with rheumatoid arthritis in 2 clinical 
trials. After at least 12 weeks of anakinra, 30 (2%) of the 1,615 patients with available data were 
seropositive in a cell-based assay for neutralizing antibodies against anakinra. Thirteen of the 30 
patients had follow-up data; 5 remained positive for neutralizing antibodies at week 24. No 
correlation between antibody development and adverse events was noted. Immunogenicity was 
not evaluated in trials of patients with Neonatal-Onset Multisystem Inflammatory Disease 
(NOMID).[27940]
The role of interleukin-1 blockers such as anakinra in the development of new primary 
malignancy is unknown. In clinical trials, the number of lymphoma cases among 5,300 patients 
with rheumatoid arthritis treated with anakinra was 0.12 per 100 patient-years. The rate is 3.6-fold 
higher than the expected rate for the general population, based upon the National Cancer Institute's 
Surveillance Epidemiology and End Results database. In addition to lymphoma, 37 other cancers 
were observed including breast, melanoma, respiratory system, and digestive system.[27940]
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Contraindications/Precautions
Absolute contraindications are italicized.
• E. coli protein hypersensitivity
• asthma 
• bone marrow suppression 
• breast-feeding 
• fungal infection 
• geriatric 
• immunosuppression 
• infants 
• infection 
• mycobacterial infection 
• neonates 
• neoplastic disease 
• neutropenia 
• new primary malignancy 
• pregnancy 
• renal failure 
• renal impairment 
• tuberculosis 
• vaccination 
Anakinra is contraindicated in patients with E. coli protein hypersensitivity or hypersensitivity to 
anakinra or any components of the product. Hypersensitivity reactions, including anaphylactic 
reactions and angioedema, have been reported with the use of anakinra. If a severe 
hypersensitivity reaction occurs, administration of anakinra should be discontinued and 
appropriate therapy initiated.[27940]
Patients who receive anakinra are at increased risk for developing serious infections. Anakinra 
should not be initiated in patients with an active infection. Administration of anakinra should be 
discontinued if a patient with rheumatoid arthritis (RA) develops a serious infection. In NOMID 
patients, the risk of a NOMID flare upon discontinuation of anakinra should be weighed against 
the potential risk of continued treatment. The safety and efficacy of anakinra in patients with 
chronic infections or immunosuppression, such as bone marrow suppression, have not been 
evaluated. The impact of anakinra therapy on active or chronic infections is not known. Similar to 
other drugs that affect the immune system, anakinra may increase the risk of tuberculosis or other 
atypical or opportunistic infections. In clinical studies and postmarketing experience, cases of 
opportunistic infections have been observed and included fungal infection, mycobacterial 
infection, and infection with bacterial pathogens. Infections have been noted in all organ systems 
and have been reported in patients receiving anakinra alone or in combination with 
immunosuppressive agents. Follow current CDC guidelines both to evaluate for and to treat 
possible latent tuberculosis infections before anakinra initiation. In RA trials, patients with asthma
appeared to be at a higher risk of developing serious infections during anakinra treatment. Also, 
anakinra should be used cautiously in geriatric patients, as there is, in general, a higher incidence 
of infections in the elderly.[27940]
Decreases in neutrophil count and neutropenia have been reported with anakinra therapy. 
Neutrophil counts should be checked before anakinra receipt, every month for 3 months, and 
quarterly after that for a period up to 1 year.[27940]
Anakinra is substantially excreted by the kidney; thus, patients with severe renal impairment or 
renal failure with a creatinine clearance (CrCL) less than 30 mL/minute may be at increased risk 
for adverse reactions. Consider administration of the prescribed anakinra dose every other day for 
these patients.[27940]
Anakinra is an immunosuppressant and treatment with immunosuppressants may result in an 
increased risk of cancer. The impact of anakinra on the development of a new primary malignancy
is unknown, but malignancies were observed in clinical studies. Consider the risks and benefits of 
anakinra before initiation in patients with a history of neoplastic disease. Also, consider the risk 
and benefits of anakinra continuation in patients who develop a malignancy.[27940]
Avoid use of live vaccines concurrently with anakinra. No data are available on either the effects 
of live vaccination or the secondary transmission of infection by live vaccines in patients receiving 
anakinra. No data are available on the effectiveness of vaccination with inactivated antigens, other 
than tetanus/diphtheria toxoids vaccine, in patients receiving anakinra. In one clinical trial, no 
difference in the anti-tetanus antibody response to tetanus/diphtheria toxoids vaccine was noted 
between patients receiving anakinra and placebo. Since anakinra interferes with normal immune 
response mechanisms to new antigens, vaccination may not be effective. The interval between live 
vaccinations and initiation of anakinra therapy should be in accordance with current vaccination 
guidelines regarding immunosuppressive agents.[27940]
Available data from retrospective studies and case reports on anakinra use during human 
pregnancy are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or 
maternal and fetal adverse events. The available data have not identified an increased frequency or 
pattern of birth defects, miscarriage, or adverse maternal or fetal outcomes. Published data do 
suggest an increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis 
(RA) or cryopyrin-associated periodic syndromes (CAPS) who have increased disease activity. An 
international retrospective study of pregnancy outcomes with interleukin-1 inhibitors reported on 
23 anakinra-exposed pregnancies. There were 21 live births of healthy infants, 1 miscarriage, and 
1 infant with left renal agenesis. The estimated background rate of detected renal malformations is 
0.2% to 2% of all newborns. Data for another retrospective study of 10 anakinra-exposed 
pregnancies in women with CAPS included 9 live births, 1 miscarriage, and 1 fetal death in a twin 
pregnancy (the surviving twin was healthy). Overall, these data cannot definitively establish or 
exclude any anakinra-associated risks during pregnancy. Methodological limitations of these data 
include small sample size and the inability to control for confounders such as the timing of drug 
exposure, underlying maternal disease, and concomitant medication use. Reproductive studies in 
animals (rats, rabbits) revealed no evidence of fetal harm at doses up to 25 times the maximum 
recommended human dose (MRHD) on an mg/kg basis.[27940] Guidelines suggest that until 
further data are available, anakinra use should be avoided during pregnancy if possible in patients 
with RA.[62180]
There are no data on the presence of anakinra in either human or animal milk or the effects on 
milk production. Limited data from a small retrospective study and postmarketing case reports do 
not establish an association between maternal anakinra use during lactation and adverse effects in 
breastfed infants. These limited data during lactation preclude a clear determination of the risk of 
anakinra to an infant during lactation. The developmental and health benefits of breast-feeding
should be considered along with the clinical need for anakinra in the mother and any potential 
adverse effects to the nursing infant from anakinra or from the underlying maternal condition.
[27940] Guidelines suggest that until further data are available, anakinra use in patients with RA 
should be approached with caution and avoided if possible during breast-feeding.[62180]
Very limited data are available describing the use of anakinra in infants; use with caution in young 
infants. Neonates and infants less than 1 month of age were not included in the trial for the 
treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Anakinra prefilled 
syringes are unable to deliver an anakinra dosage less than 20 mg. Although anakinra has been 
studied in pediatric patients 2 to 17 years of age with juvenile rheumatoid arthritis (JRA)/juvenile 
idiopathic arthritis (JIA), the study data were insufficient to demonstrate efficacy.[27940]
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Mechanism of Action
Anakinra acts similarly to the native interleukin-1 receptor antagonist (IL-1Ra). IL-1Ra blocks the 
effects of IL-1 by competitively inhibiting the binding of IL-1, specifically IL-1alpha and IL-
1beta, to the interleukin-1 type 1 receptor (IL-1R1), which is expressed in a wide variety of 
tissues. IL-1Ra is part of the feedback loop that is designed to balance the effects of inflammatory 
cytokines. IL-1 is one of the primary pro-inflammatory cytokines associated with rheumatoid 
arthritis, acting synergistically with tumor necrosis factor-alpha (TNF-alpha). Both IL-1 and TNF-
alpha are expressed in the synovium of rheumatoid arthritis patients, although, IL-1, specifically 
IL-1beta, is secreted to a greater extent than TNF-alpha. IL-1 causes cartilage degradation by 
inducing the rapid loss of proteoglycans and stimulating the production of neutral proteinases in 
chondrocytes. Since IL-1 stimulates osteoclasts, bone resorption occurs. Rheumatoid arthritis 
patients who have bone erosions also have higher synovial fluid levels of IL-1 than rheumatoid 
arthritis patients with no bone erosions. These higher levels of IL-1 cannot be overcome by 
endogenous IL-1Ra. By administering exogenous IL-1Ra (i.e., anakinra), the erosive bone effects 
and bone resorption associated with IL-1 may be inhibited.[27940][65258]
The efficacy of anakinra for the treatment of familial cold autoinflammatory syndrome appears to 
be related to inhibition of IL-1beta, IL-6, and IL-8 in affected skin and to inhibition of increased 
IL-6 serum concentrations after cold exposure.[33471] In excess, IL-1 has been shown to be a key 
driver of inflammation in cryopyrin-associated periodic syndromes (CAPS), which is caused by a 
range of mutations in the gene CIAS1 that encodes the protein cryopyrin. Cryopyrin binds with an 
intrinsic inhibitor and controls the activation of caspase-1. Caspase-1 cleaves pro-interleukin-
1beta and IL-18 into the biologically active forms. Patients with CAPS have increased caspase 
activity and thus, increased biologically active IL-1 beta. Enhanced caspase-1 activity with 
subsequent enhanced IL-1 beta and IL-18 release has been demonstrated in a patient with chronic 
infantile neurologic, cutaneous, articular (CINCA) syndrome.[33840] Anakinra receipt to several 
patients with different CAPS phenotypes led to the reduction of many CAPS clinical 
manifestations.[27940]
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Pharmacokinetics
Anakinra is given subcutaneously. In patients with rheumatoid arthritis (RA), no unexpected 
accumulation of anakinra was observed after daily subcutaneous doses for up to 24 weeks. The 
terminal half-life of anakinra ranges from 4 to 6 hours among patients with RA. Among patients 
with Neonatal Onset Multisystem Inflammatory Disease (NOMID), the median half-life was 5.7 
hours (range, 3.1 to 28.2 hours). Anakinra is renally eliminated; the mean clearance of the drug 
increases with increasing creatinine clearance and body weight.[27940]
Route-Specific Pharmacokinetics
• Subcutaneous Route
The absolute bioavailability of anakinra after subcutaneous injection in healthy 
subjects is 95%. After administration to subjects with RA, the maximum plasma 
concentration occurs within 3 to 7 hours. In NOMID patients (n = 16) receiving a 
median dose of 3 mg/kg once daily subcutaneously and a median treatment time of 3.5 
years, the steady-state median (range) maximal concentration (Cmax) was 3,628 (655 
to 8,511) ng/mL and the median (range) 24-hour concentration was 203 (53 to 1,979) 
ng/mL.[27940]
Special Populations
• Hepatic Impairment
No formal studies have been performed to examine the pharmacokinetic parameters of 
anakinra administered subcutaneously in patients with hepatic impairment.[27940]
• Renal Impairment
The estimated anakinra clearance increased with increasing creatinine clearance and 
body weight in a pharmacokinetic study using daily subcutaneous doses of anakinra. 
Among patients with severe or end-stage renal disease, defined as creatinine clearance 
(CrCl) less than 30 mL/minute, the mean plasma clearance of anakinra decreased by 
70% and 75%, respectively. The mean plasma clearance of anakinra decreased by 50% 
in patients with a CrCl of 30 to 49 mL/minute and by 16% in patients with a CrCl of 50 
to 80 mL/minute. Less than 2.5% of an administered dose is removed by either 
hemodialysis or continuous ambulatory peritoneal dialysis. Based on these 
observations, a dose schedule change should be considered for subjects with severe 
renal insufficiency or end-stage renal disease.[27940]
• Geriatric
After adjusting for creatinine clearance and body weight, age was not a significant 
factor for the mean plasma clearance of anakinra during a pharmacokinetic study.
[27940]
• Gender Differences
After adjusting for creatinine clearance and body weight, gender was not a significant 
factor for the mean plasma clearance of anakinra in a pharmacokinetic study. In a study 
of NOMID patients, there was no obvious gender influence on anakinra 
pharmacokinetics.[27940]
• Obesity
The estimated anakinra clearance increased with increasing creatinine clearance and 
body weight in a pharmacokinetic study.[27940]
Revision Date: 04/15/2020 12:10:15 PM 
References
27940 – Kineret (anakinra) package insert. Stockholm, Sweden: Swedish Orphan Biovitrum AB; 
2018 Jun.
Pregnancy/Breast-feeding
Pregnancy
Available data from retrospective studies and case reports on anakinra use during human 
pregnancy are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or 
maternal and fetal adverse events. The available data have not identified an increased frequency or 
pattern of birth defects, miscarriage, or adverse maternal or fetal outcomes. Published data do 
suggest an increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis 
(RA) or cryopyrin-associated periodic syndromes (CAPS) who have increased disease activity. An 
international retrospective study of pregnancy outcomes with interleukin-1 inhibitors reported on 
23 anakinra-exposed pregnancies. There were 21 live births of healthy infants, 1 miscarriage, and 
1 infant with left renal agenesis. The estimated background rate of detected renal malformations is 
0.2% to 2% of all newborns. Data for another retrospective study of 10 anakinra-exposed 
pregnancies in women with CAPS included 9 live births, 1 miscarriage, and 1 fetal death in a twin 
pregnancy (the surviving twin was healthy). Overall, these data cannot definitively establish or 
exclude any anakinra-associated risks during pregnancy. Methodological limitations of these data 
include small sample size and the inability to control for confounders such as the timing of drug 
exposure, underlying maternal disease, and concomitant medication use. Reproductive studies in 
animals (rats, rabbits) revealed no evidence of fetal harm at doses up to 25 times the maximum 
recommended human dose (MRHD) on an mg/kg basis.[27940] Guidelines suggest that until 
further data are available, anakinra use should be avoided during pregnancy if possible in patients 
with RA.[62180]
Breast-Feeding
There are no data on the presence of anakinra in either human or animal milk or the effects on 
milk production. Limited data from a small retrospective study and postmarketing case reports do 
not establish an association between maternal anakinra use during lactation and adverse effects in 
breastfed infants. These limited data during lactation preclude a clear determination of the risk of 
anakinra to an infant during lactation. The developmental and health benefits of breast-feeding 
should be considered along with the clinical need for anakinra in the mother and any potential 
adverse effects to the nursing infant from anakinra or from the underlying maternal condition.
[27940] Guidelines suggest that until further data are available, anakinra use in patients with RA 
should be approached with caution and avoided if possible during breast-feeding.[62180]
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Interactions
Level 2 (Major)
• Abatacept
• Adalimumab
• Bacillus Calmette-Guerin Vaccine, BCG
• Baricitinib
• Canakinumab
• Certolizumab pegol
• Etanercept
• Golimumab
• Infliximab
• Influenza Virus Vaccine
• Intranasal Influenza Vaccine
• Live Vaccines
• Measles Virus; Mumps Virus; Rubella 
Virus; Varicella Virus Vaccine, Live
• Measles/Mumps/Rubella Vaccines, 
MMR
• Rilonacept
• Rituximab
• Rituximab; Hyaluronidase
• Rotavirus Vaccine
• Rubella Virus Vaccine Live
• Sarilumab
• Smallpox and Monkeypox Vaccine, 
Live, Nonreplicating
• Smallpox Vaccine, Vaccinia Vaccine
• Tocilizumab
• Tofacitinib
• Tumor Necrosis Factor modifiers
• Typhoid Vaccine
• Upadacitinib
• Varicella-Zoster Virus Vaccine, Live
• Yellow Fever Vaccine, Live
Level 3 (Moderate)
• Tuberculin Purified Protein Derivative, PPD
Abatacept: (Major) Concomitant use of abatacept with biological DMARDs, such as anakinra, is 
not recommended because of the possibility of additive immunosuppression and increased risk of 
infection. There is insufficient experience to assess the safety and efficacy of abatacept 
administered concurrently with anakinra. [27940] [31761]
Adalimumab: (Major) Avoid the concomitant use of anakinra with biological DMARDs, such as 
tumor necrosis factor (TNF) modifiers; coadministration has not been studied and may result in 
additive immunosuppression and increased risk of infection with no additional clinical benefit. 
Data suggest a higher rate of serious infections when anakinra and a TNF inhibitor is used in 
combination with anakinra compared with either drug given alone. Neutropenia (1,000/mcL or 
less) was observed in 2% of patients receiving the combination. The use of anakinra with a TNF 
inhibitor in combination did not yield any additional clinical benefit as compared to the use of the 
TNF inhibitor alone. [27939] [27940] [27994] [28060] [33930] [35501]
Bacillus Calmette-Guerin Vaccine, BCG: (Major) Avoid concurrent use of live vaccines during 
treatment with anakinra due to potentially increased risk of infections; clinical safety of live 
vaccines during anakinra treatment has not been established. Live virus vaccines should generally 
not be administered to an immunosuppressed patient, as they may induce the illness they are 
intended to prevent. The immune response of the immunocompromised patient to vaccines may be 
decreased, even despite alternate vaccination schedules or more frequent booster doses. If 
immunization is necessary, choose an alternative to live vaccination, or, consider a delay or 
change in the immunization schedule. No data are available on the secondary transmission of 
infection from persons receiving live vaccines to patients receiving anakinra. The interval between 
live vaccinations and initiation of anakinra therapy should be in accordance with current 
vaccination guidelines regarding immunosuppressive agents. [27940] [43236]
Baricitinib: (Major) Concomitant use of baricitinib with biologic DMARDs, such as anakinra, is 
not recommended because of the possibility of increased immunosuppression and increased 
infection risk. Baricitinib may be used as monotherapy or concomitantly with methotrexate or 
other nonbiologic DMARDs. [63229]
Canakinumab: (Major) Concomitant use of anakinra with other drugs that also block interleukin 
(IL)-1, such as canakinumab, is not recommended; coadministration has not been studied and may 
result in additive immunosuppression and increased risk of infection. [27940] [41378]
Certolizumab pegol: (Major) Avoid the concomitant use of anakinra with biological DMARDs, 
such as tumor necrosis factor (TNF) modifiers; coadministration has not been studied and may 
result in additive immunosuppression and increased risk of infection with no additional clinical 
benefit. Data suggest a higher rate of serious infections when anakinra and a TNF inhibitor is used 
in combination with anakinra compared with either drug given alone. Neutropenia (1,000/mcL or 
less) was observed in 2% of patients receiving the combination. The use of anakinra with a TNF 
inhibitor in combination did not yield any additional clinical benefit as compared to the use of the 
TNF inhibitor alone. [27939] [27940] [27994] [28060] [33930] [35501]
Etanercept: (Major) Avoid the concomitant use of anakinra with biological DMARDs, such as 
tumor necrosis factor (TNF) modifiers; coadministration has not been studied and may result in 
additive immunosuppression and increased risk of infection with no additional clinical benefit. 
Data suggest a higher rate of serious infections when anakinra and a TNF inhibitor is used in 
combination with anakinra compared with either drug given alone. Neutropenia (1,000/mcL or 
less) was observed in 2% of patients receiving the combination. The use of anakinra with a TNF 
inhibitor in combination did not yield any additional clinical benefit as compared to the use of the 
TNF inhibitor alone. [27939] [27940] [27994] [28060] [33930] [35501]
Golimumab: (Major) Avoid the concomitant use of anakinra with biological DMARDs, such as 
tumor necrosis factor (TNF) modifiers; coadministration has not been studied and may result in 
additive immunosuppression and increased risk of infection with no additional clinical benefit. 
Data suggest a higher rate of serious infections when anakinra and a TNF inhibitor is used in 
combination with anakinra compared with either drug given alone. Neutropenia (1,000/mcL or 
less) was observed in 2% of patients receiving the combination. The use of anakinra with a TNF 
inhibitor in combination did not yield any additional clinical benefit as compared to the use of the 
TNF inhibitor alone. [27939] [27940] [27994] [28060] [33930] [35501]
Infliximab: (Major) Avoid the concomitant use of anakinra with biological DMARDs, such as 
tumor necrosis factor (TNF) modifiers; coadministration has not been studied and may result in 
additive immunosuppression and increased risk of infection with no additional clinical benefit. 
Data suggest a higher rate of serious infections when anakinra and a TNF inhibitor is used in 
combination with anakinra compared with either drug given alone. Neutropenia (1,000/mcL or 
less) was observed in 2% of patients receiving the combination. The use of anakinra with a TNF 
inhibitor in combination did not yield any additional clinical benefit as compared to the use of the 
TNF inhibitor alone. [27939] [27940] [27994] [28060] [33930] [35501]
Influenza Virus Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with 
anakinra due to potentially increased risk of infections; clinical safety of live vaccines during 
anakinra treatment has not been established. Live virus vaccines should generally not be 
administered to an immunosuppressed patient, as they may induce the illness they are intended to 
prevent. The immune response of the immunocompromised patient to vaccines may be decreased, 
even despite alternate vaccination schedules or more frequent booster doses. If immunization is 
necessary, choose an alternative to live vaccination, or, consider a delay or change in the 
immunization schedule. No data are available on the secondary transmission of infection from 
persons receiving live vaccines to patients receiving anakinra. The interval between live 
vaccinations and initiation of anakinra therapy should be in accordance with current vaccination 
guidelines regarding immunosuppressive agents. [27940] [43236]
Intranasal Influenza Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with 
anakinra due to potentially increased risk of infections; clinical safety of live vaccines during 
anakinra treatment has not been established. Live virus vaccines should generally not be 
administered to an immunosuppressed patient, as they may induce the illness they are intended to 
prevent. The immune response of the immunocompromised patient to vaccines may be decreased, 
even despite alternate vaccination schedules or more frequent booster doses. If immunization is 
necessary, choose an alternative to live vaccination, or, consider a delay or change in the 
immunization schedule. No data are available on the secondary transmission of infection from 
persons receiving live vaccines to patients receiving anakinra. The interval between live 
vaccinations and initiation of anakinra therapy should be in accordance with current vaccination 
guidelines regarding immunosuppressive agents. [27940] [43236]
Live Vaccines: (Major) Avoid concurrent use of live vaccines during treatment with anakinra due 
to potentially increased risk of infections; clinical safety of live vaccines during anakinra 
treatment has not been established. Live virus vaccines should generally not be administered to an 
immunosuppressed patient, as they may induce the illness they are intended to prevent. The 
immune response of the immunocompromised patient to vaccines may be decreased, even despite 
alternate vaccination schedules or more frequent booster doses. If immunization is necessary, 
choose an alternative to live vaccination, or, consider a delay or change in the immunization 
schedule. No data are available on the secondary transmission of infection from persons receiving 
live vaccines to patients receiving anakinra. The interval between live vaccinations and initiation 
of anakinra therapy should be in accordance with current vaccination guidelines regarding 
immunosuppressive agents. [27940] [43236]
Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live: (Major) Avoid 
concurrent use of live vaccines during treatment with anakinra due to potentially increased risk of 
infections; clinical safety of live vaccines during anakinra treatment has not been established. Live 
virus vaccines should generally not be administered to an immunosuppressed patient, as they may 
induce the illness they are intended to prevent. The immune response of the immunocompromised 
patient to vaccines may be decreased, even despite alternate vaccination schedules or more 
frequent booster doses. If immunization is necessary, choose an alternative to live vaccination, or, 
consider a delay or change in the immunization schedule. No data are available on the secondary 
transmission of infection from persons receiving live vaccines to patients receiving anakinra. The 
interval between live vaccinations and initiation of anakinra therapy should be in accordance with 
current vaccination guidelines regarding immunosuppressive agents. [27940] [43236]
Measles/Mumps/Rubella Vaccines, MMR: (Major) Avoid concurrent use of live vaccines during 
treatment with anakinra due to potentially increased risk of infections; clinical safety of live 
vaccines during anakinra treatment has not been established. Live virus vaccines should generally 
not be administered to an immunosuppressed patient, as they may induce the illness they are 
intended to prevent. The immune response of the immunocompromised patient to vaccines may be 
decreased, even despite alternate vaccination schedules or more frequent booster doses. If 
immunization is necessary, choose an alternative to live vaccination, or, consider a delay or 
change in the immunization schedule. No data are available on the secondary transmission of 
infection from persons receiving live vaccines to patients receiving anakinra. The interval between 
live vaccinations and initiation of anakinra therapy should be in accordance with current 
vaccination guidelines regarding immunosuppressive agents. [27940] [43236]
Rilonacept: (Major) Concomitant use of anakinra with other drugs that also block interleukin 
(IL)-1, such as rilonacept, is not recommended; coadministration has not been studied and may 
result in additive immunosuppression and increased risk of infection. [27940] [33837]
Rituximab: (Major) Utilize caution with concomitant use of rituximab with other biologic agents, 
such as anakinra; coadministration may result in additive immunosuppression and an increased 
risk of infection. Limited data are available on the safety of the use of biologic agents in 
rheumatoid arthritis patients exhibiting peripheral B-cell depletion following treatment with 
rituximab. Monitor patients closely for signs or symptoms of infection. [27940] [49773]
Rituximab; Hyaluronidase: (Major) Utilize caution with concomitant use of rituximab with other 
biologic agents, such as anakinra; coadministration may result in additive immunosuppression and 
an increased risk of infection. Limited data are available on the safety of the use of biologic agents 
in rheumatoid arthritis patients exhibiting peripheral B-cell depletion following treatment with 
rituximab. Monitor patients closely for signs or symptoms of infection. [27940] [49773]
Rotavirus Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with anakinra 
due to potentially increased risk of infections; clinical safety of live vaccines during anakinra 
treatment has not been established. Live virus vaccines should generally not be administered to an 
immunosuppressed patient, as they may induce the illness they are intended to prevent. The 
immune response of the immunocompromised patient to vaccines may be decreased, even despite 
alternate vaccination schedules or more frequent booster doses. If immunization is necessary, 
choose an alternative to live vaccination, or, consider a delay or change in the immunization 
schedule. No data are available on the secondary transmission of infection from persons receiving 
live vaccines to patients receiving anakinra. The interval between live vaccinations and initiation 
of anakinra therapy should be in accordance with current vaccination guidelines regarding 
immunosuppressive agents. [27940] [43236]
Rubella Virus Vaccine Live: (Major) Avoid concurrent use of live vaccines during treatment with 
anakinra due to potentially increased risk of infections; clinical safety of live vaccines during 
anakinra treatment has not been established. Live virus vaccines should generally not be 
administered to an immunosuppressed patient, as they may induce the illness they are intended to 
prevent. The immune response of the immunocompromised patient to vaccines may be decreased, 
even despite alternate vaccination schedules or more frequent booster doses. If immunization is 
necessary, choose an alternative to live vaccination, or, consider a delay or change in the 
immunization schedule. No data are available on the secondary transmission of infection from 
persons receiving live vaccines to patients receiving anakinra. The interval between live 
vaccinations and initiation of anakinra therapy should be in accordance with current vaccination 
guidelines regarding immunosuppressive agents. [27940] [43236]
Sarilumab: (Major) Avoid using sarilumab with other biological DMARDs including interleukin-1 
receptor antagonists such as anakinra; coadministration has not been studied and may result in 
additive immunosuppression and increased risk of infection. [61976]
Smallpox and Monkeypox Vaccine, Live, Nonreplicating: (Major) Avoid concurrent use of live 
vaccines during treatment with anakinra due to potentially increased risk of infections; clinical 
safety of live vaccines during anakinra treatment has not been established. Live virus vaccines 
should generally not be administered to an immunosuppressed patient, as they may induce the 
illness they are intended to prevent. The immune response of the immunocompromised patient to 
vaccines may be decreased, even despite alternate vaccination schedules or more frequent booster 
doses. If immunization is necessary, choose an alternative to live vaccination, or, consider a delay 
or change in the immunization schedule. No data are available on the secondary transmission of 
infection from persons receiving live vaccines to patients receiving anakinra. The interval between 
live vaccinations and initiation of anakinra therapy should be in accordance with current 
vaccination guidelines regarding immunosuppressive agents. [27940] [43236]
Smallpox Vaccine, Vaccinia Vaccine: (Major) Avoid concurrent use of live vaccines during 
treatment with anakinra due to potentially increased risk of infections; clinical safety of live 
vaccines during anakinra treatment has not been established. Live virus vaccines should generally 
not be administered to an immunosuppressed patient, as they may induce the illness they are 
intended to prevent. The immune response of the immunocompromised patient to vaccines may be 
decreased, even despite alternate vaccination schedules or more frequent booster doses. If 
immunization is necessary, choose an alternative to live vaccination, or, consider a delay or 
change in the immunization schedule. No data are available on the secondary transmission of 
infection from persons receiving live vaccines to patients receiving anakinra. The interval between 
live vaccinations and initiation of anakinra therapy should be in accordance with current 
vaccination guidelines regarding immunosuppressive agents. [27940] [43236]
Tocilizumab: (Major) Avoid the concomitant use of tocilizumab with biological DMARDs, 
including interleukin-1 receptor antagonists such as anakinra; coadministration has not been 
studied and may result in additive immunosuppression and increased risk of infection. [27940]
[38283]
Tofacitinib: (Major) Avoid concomitant use of tofacitinib with biologic DMARDs, such as 
anakinra; coadministration has not been studied and may result in additive immunosuppression 
and increased risk of infection. [52315]
Tuberculin Purified Protein Derivative, PPD: (Moderate) Since anakinra interferes with normal 
immune response mechanisms to new antigens such as tuberculin purified protein derivative, PPD, 
reactivity to the test may be decreased. Consider deferring the skin test until completion of 
anakinra therapy. [43298] [43299] [4656]
Tumor Necrosis Factor modifiers: (Major) Avoid the concomitant use of anakinra with biological 
DMARDs, such as tumor necrosis factor (TNF) modifiers; coadministration has not been studied 
and may result in additive immunosuppression and increased risk of infection with no additional 
clinical benefit. Data suggest a higher rate of serious infections when anakinra and a TNF inhibitor 
is used in combination with anakinra compared with either drug given alone. Neutropenia 
(1,000/mcL or less) was observed in 2% of patients receiving the combination. The use of 
anakinra with a TNF inhibitor in combination did not yield any additional clinical benefit as 
compared to the use of the TNF inhibitor alone. [27939] [27940] [27994] [28060] [33930] [35501]
Typhoid Vaccine: (Major) Avoid concurrent use of live vaccines during treatment with anakinra 
due to potentially increased risk of infections; clinical safety of live vaccines during anakinra 
treatment has not been established. Live virus vaccines should generally not be administered to an 
immunosuppressed patient, as they may induce the illness they are intended to prevent. The 
immune response of the immunocompromised patient to vaccines may be decreased, even despite 
alternate vaccination schedules or more frequent booster doses. If immunization is necessary, 
choose an alternative to live vaccination, or, consider a delay or change in the immunization 
schedule. No data are available on the secondary transmission of infection from persons receiving 
live vaccines to patients receiving anakinra. The interval between live vaccinations and initiation 
of anakinra therapy should be in accordance with current vaccination guidelines regarding 
immunosuppressive agents. [27940] [43236]
Upadacitinib: (Major) Avoid the concomitant use of upadacitinib with biologic DMARDs, such as 
anakinra; coadministration has not been studied and may result in additive immunosuppression 
and increased risk of infection. [64572]
Varicella-Zoster Virus Vaccine, Live: (Major) Avoid concurrent use of live vaccines during 
treatment with anakinra due to potentially increased risk of infections; clinical safety of live 
vaccines during anakinra treatment has not been established. Live virus vaccines should generally 
not be administered to an immunosuppressed patient, as they may induce the illness they are 
intended to prevent. The immune response of the immunocompromised patient to vaccines may be 
decreased, even despite alternate vaccination schedules or more frequent booster doses. If 
immunization is necessary, choose an alternative to live vaccination, or, consider a delay or 
change in the immunization schedule. No data are available on the secondary transmission of 
infection from persons receiving live vaccines to patients receiving anakinra. The interval between 
live vaccinations and initiation of anakinra therapy should be in accordance with current 
vaccination guidelines regarding immunosuppressive agents. [27940] [43236]
Yellow Fever Vaccine, Live: (Major) Avoid concurrent use of live vaccines during treatment with 
anakinra due to potentially increased risk of infections; clinical safety of live vaccines during 
anakinra treatment has not been established. Live virus vaccines should generally not be 
administered to an immunosuppressed patient, as they may induce the illness they are intended to 
prevent. The immune response of the immunocompromised patient to vaccines may be decreased, 
even despite alternate vaccination schedules or more frequent booster doses. If immunization is 
necessary, choose an alternative to live vaccination, or, consider a delay or change in the 
immunization schedule. No data are available on the secondary transmission of infection from 
persons receiving live vaccines to patients receiving anakinra. The interval between live 
vaccinations and initiation of anakinra therapy should be in accordance with current vaccination 
guidelines regarding immunosuppressive agents. [27940] [43236]
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Monitoring Parameters
• CBC with differential
• tuberculin skin test
IV Compatibility of Anakinra with:
Legend
 = Compatible
 = Incompatible
 = Results uncertain, variable or dependent on conditions
ND = No Data Available
From Trissel's 2™ Clinical Pharmaceutics Database 
Admixture Syringe Y-Site Administration For Dilution
Aztreonam ND ND ND 
Cefazolin sodium ND ND ND 
Cefotaxime ND ND ND 
Cefoxitin ND ND ND 
Ceftazidime ND ND ND 
Ceftriaxone sodium ND ND ND 
Cefuroxime ND ND ND 
Cimetidine hydrochloride ND ND ND 
Ciprofloxacin ND ND ND 
Clindamycin phosphate ND ND ND 
Famotidine ND ND ND 
Fluconazole ND ND ND 
Lorazepam ND ND ND 
Morphine sulfate ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Ondansetron hydrochloride ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Piperacillin sodium ND ND ND 
Ranitidine hydrochloride ND ND ND 
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US Drug Names
• Kineret
Global Drug names
Australia
• Kineret - (Menarini)
Austria
• Kineret - (Biovitrum)
Belgium
• Kineret - (Swedish Orphan)
Canada
• Kineret - (Amgen)
Czech Republic
• Kineret - (Swedish Orphan)
Denmark
• Kineret - (Swedish Orphan)
Finland
• Kineret - (Swedish Orphan)
France
• Kineret - (Biovitrum)
Germany
• Kineret - (Swedish Orphan)
Greece
• Kineret - (Biovitrum)
Hungary
• Kineret - (Swedish Orphan)
Ireland
• Kineret - (Swedish Orphan)
Israel
• Kineret - (Megapharm)
Italy
• Kineret - (Biovitrum)
Netherlands
• Kineret - (Swedish Orphan)
Norway
• Kineret - (Swedish Orphan)
Poland
• Kineret - (Amgen)
Portugal
• Kineret - (Biovitrum)
Singapore
• Kineret - (Swedish Orphan)
Spain
• Kineret - (Biovitrum)
Sweden
• Kineret - (Biovitrum)
United Kingdom
• Kineret - (Swedish Orphan)
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